» Articles » PMID: 18060075

Effects of Blood Collection Conditions on Ovarian Cancer Serum Markers

Overview
Journal PLoS One
Date 2007 Dec 7
PMID 18060075
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Evaluating diagnostic and early detection biomarkers requires comparing serum protein concentrations among biosamples ascertained from subjects with and without cancer. Efforts are generally made to standardize blood processing and storage conditions for cases and controls, but blood sample collection conditions cannot be completely controlled. For example, blood samples from cases are often obtained from persons aware of their diagnoses, and collected after fasting or in surgery, whereas blood samples from some controls may be obtained in different conditions, such as a clinic visit. By measuring the effects of differences in collection conditions on three different markers, we investigated the potential of these effects to bias validation studies.

Methodology And Principle Findings: We analyzed serum concentrations of three previously studied putative ovarian cancer serum biomarkers-CA 125, Prolactin and MIF-in healthy women, women with ovarian cancer undergoing gynecologic surgery, women undergoing surgery for benign ovary pathology, and women undergoing surgery with pathologically normal ovaries. For women undergoing surgery, a blood sample was collected either in the clinic 1 to 39 days prior to surgery, or on the day of surgery after anesthesia was administered but prior to the surgical procedure, or both. We found that one marker, prolactin, was dramatically affected by collection conditions, while CA 125 and MIF were unaffected. Prolactin levels were not different between case and control groups after accounting for the conditions of sample collection, suggesting that sample ascertainment could explain some or all of the previously reported results about its potential as a biomarker for ovarian cancer.

Conclusions: Biomarker validation studies should use standardized collection conditions, use multiple control groups, and/or collect samples from cases prior to influence of diagnosis whenever feasible to detect and correct for potential biases associated with sample collection.

Citing Articles

Preoperative Fasting and General Anaesthesia Alter the Plasma Proteome.

Gyllensten U, Bosdotter Enroth S, Stalberg K, Sundfeldt K, Enroth S Cancers (Basel). 2020; 12(9).

PMID: 32867270 PMC: 7564209. DOI: 10.3390/cancers12092439.


Tumor Pre-Analytics in Molecular Pathology: Impact on Protein Expression and Analysis.

Neumeister V, Juhl H Curr Pathobiol Rep. 2019; 6(4):265-274.

PMID: 30595971 PMC: 6290693. DOI: 10.1007/s40139-018-0179-5.


Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers.

Cohen J, Javed A, Thoburn C, Wong F, Tie J, Gibbs P Proc Natl Acad Sci U S A. 2017; 114(38):10202-10207.

PMID: 28874546 PMC: 5617273. DOI: 10.1073/pnas.1704961114.


Epigenome-wide discovery and evaluation of leukocyte DNA methylation markers for the detection of colorectal cancer in a screening setting.

Heiss J, Brenner H Clin Epigenetics. 2017; 9:24.

PMID: 28270869 PMC: 5335821. DOI: 10.1186/s13148-017-0322-x.


The Pursuit of Noninvasive Diagnosis of Lung Cancer.

Atwater T, Cook C, Massion P Semin Respir Crit Care Med. 2016; 37(5):670-680.

PMID: 27732989 PMC: 5317274. DOI: 10.1055/s-0036-1592314.


References
1.
Skates S, Menon U, MacDonald N, Rosenthal A, Oram D, Knapp R . Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol. 2003; 21(10 Suppl):206s-210s. DOI: 10.1200/JCO.2003.02.955. View

2.
Hagen C, Brandt M, Kehlet H . Prolactin, LH, FSH, GH and cortisol response to surgery and the effect of epidural analgesia. Acta Endocrinol (Copenh). 1980; 94(2):151-4. DOI: 10.1530/acta.0.0940151. View

3.
Niloff J, Knapp R, Lavin P, MALKASIAN G, Berek J, Mortel R . The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol. 1986; 155(1):56-60. DOI: 10.1016/0002-9378(86)90077-3. View

4.
Scholler N, Crawford M, Sato A, Drescher C, OBriant K, Kiviat N . Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res. 2006; 12(7 Pt 1):2117-24. PMC: 2734269. DOI: 10.1158/1078-0432.CCR-05-2007. View

5.
Daoud E, BODOR G . CA-125 concentrations in malignant and nonmalignant disease. Clin Chem. 1991; 37(11):1968-74. View